drugset / Trial / NCT06932744
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.
Timeline
- Start
- 2024-08-30
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Eculizumab | Monoclonal antibody | — | — |
| Subject | MY008211A | Unknown | 400 mg | Oral |